Evaluation of Hemostasis in Female Dogs with Mammary Carcinoma and the Influence of Clinical Stage and Histopathological Grade

Jéssica Rodrigues de Oliveira, Annelise Carla Camplesi, Sabryna Gouveia Calazans, Aureo Evangelista Santana, Priscila Silva, Bruna Fernanda Firmo, Amanda Bizare, Márcia Ferreira da Rosa Sobreira

Abstract


Background: Mammary tumors are frequent in female dogs, and are biologically similar in female dogs and humans. Hemostatic disorders are common in humans with cancer, and the mechanisms that conduct coagulation activation involve tissue and cancer procoagulant factors and inflammatory cytokines. Despite the importance of coagulopathy diagnosis that evaluate hemostasis, veterinarians rarely request such tests in routine clinical oncology. This study aimed to investigate the possible hemostatic abnormalities in female dogs with mammary carcinomas and assess any associations with prognostic factors for mammary cancer in female dogs.
Materials, Methods& Results: A total of 62 female dogs were selected for inclusion in this study regardless of age or breed. The control group consisted of 30 healthy dogs, and the carcinoma group consisted of 32 dogs with a histopathological diagnosis of mammary carcinoma that was free of distant metastases and comorbidities that could interfere with the hemostatic system integrity. The dogs with mammary carcinoma were divided into subgroups according to their histological type, histopathological grading, tumor size, and clinical stage of the disease (TNM) to evaluate the relationships between the subgroups and hemostatic parameters (blood platelet counts, prothrombin time [PT], activated partial thromboplastin time [aPTT], and plasma fibrinogen concentration). The hemostatic parameters were significantly higher in the carcinoma group than in the control group (p ≤ 0.05). These findings indicate that there is a strong association between the occurrence of mammary carcinoma and abnormal hemostatic parameters, as well as a strong association between histopathological grade I and normal hemostatic parameters. In addition, when evaluating subgroups, PT and aPTT values were significantly higher in dogs with histopathological grade II and III tumors than in dogs with histopathological grade I tumors. Furthermore, PT and aPTT values were higher in the clinical stage IV subgroup than in the remaining subgroups. Nonetheless, there was no statistical difference in these values among the clinical stage I, III, and IV subgroups.
Discussion: Recent studies demonstrated that thrombocytosis is a common finding in dogs with cancer and that the true incidence of thrombocytosis might be underreported. The prolonged PT and aPTT observed in this study were higher than those described in the literature. The abnormalities in PT and aPTT values detected in female dogs with mammary carcinoma in this study might have been affected by the histopathological severity (grades II and III) and clinical disease stage. Hyperfibrinogenemia detected in the healthy control group was the most common hemostatic abnormality. This finding was close to that found in the literature, in which 66.7% of female dogs presented with high fibrinogen values, which was more evident in dogs of clinical disease stages III and IV. The results indicate that 56% of animals presented with at least three hemostatic abnormalities, including the prolongation of PT and aPTT and hyperfibrinogenemia. These abnormalities were related to advanced clinical stages and histopathological grades II and III. Thus, the observed abnormalities can be indicative of a poorer prognosis and survival time of these patients because the previously identified products of coagulation are important for both tumor dissemination and progression.


Full Text:

PDF

References


Andreasen E.B., Tranholm M., Wiinberg B., Markussen B. & Kristensen A.T. 2012. Hemostatic alterations in a group of canine cancer patients are associated with cancer type and disease progression. Acta Veterinaria Scandinavica. 54(3): 1-8.

Bogenrieder T. & Herlyn M. 2003. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 22(42): 6524-6536.

Brooks M.B. & Laforcade A. 2010. Acquired coagulopathies. In: Schalm’s Veterinary Hematology. Ames: Blackwell Publishing, pp.654-660.

Cassali G.D., Lavalle G.E., Ferreira E., Estrela-lima A., De nardi A.B., Ghever C., Sobral R.A., Amorim R.L., Oliveira L.O., Sueiro F.A.R., Beserra H.E.O., Bertagnolli A.C., Gamba C.O., Damasceno K.A., Campos C.B., Araujo M.R., Campos L.C., Monteiro L.N., Nunes F.C., Horta R.S., Reis D.C., Luvizott M.C.R., Magalhães G.M., Raposo J.B., Ferreira A.M.R., Tanaka N.M., Grandi F., Ubukata R., Batschinski K., Terra E.M., Salvador R.C.L., Jark P.C., Delecrodi J.E.R., Nascimento N.A., Silva D.N., Silva L.P., Ferreira K.C.R.S., Frehse M.S., Di santis G.W., Silva E.O., Guim T.N., Kerr B., Cintra P.P., Silva F.B.F., Leite J.S., Mello M.F.V., Ferreira M.L.G., Fukumasu H., Salgado B.S. & Torres R. 2014. Consensus for the Diagnosis, Prognosis and Treatment of Canine Mammary Tumors. Brazilian Journal of Veterinary Pathology. 7(2): 38-69.

Childress O.M. 2012. Hematologic Abnormalities in the Small Animal Cancer Patient. Veterinary Clinics of North America: Small Animal Practice. 42(1): 123-155.

Desancho M.T. & Rand J.H. 2010. Coagulopathic complications of cancer patients. In: Cancer medicine. In: Hong W.K., Bast R.C., Hait W.N., Kufe D.W., Pollock R.E., Weichselbaum R.R., Holland J.F. & Frei E. III. (Eds). 8th edn. Selton: PMPH-USA, pp.1813-1822.

Duda N.C.B., Valle S.F., Matheus J.P., Angeli N.C., Vieira L.O., Sonne L. & González F.H.D. 2017. Paraneoplastic hematological, biochemical, and hemostatic abnormalities in female dogs with mammary neoplasms. Pesquisa Veterinária Brasileira. 37(5): 479-484.

Edwards R.L., Rickles F.R., Moritz T.E., Henderson W.G., Zacharski L.R., Forman W.B., Cornelli C.J., Forcier R.J., O'donnell J.F., Headley E., Kim S.H., O'dell R., Tornyos K. & Kwaan H.C. 1987. Abnormalities of blood coagulation tests in patients with cancer. American Journal of Clinical Pathology. 88(5): 596-602.

Elston C.W. & Ellis I.O. 1998. Assessment of histological grade. In: Elston C.W. & Ellis I.O. (Eds). Systemic pathology - The breast. London: Churchill & Livingstone, pp.365-384.

Falanga A., Marchetti M. & Russo L. 2015. The mechanisms of cancer-associated thrombosis. Thrombosis Research. 135(Suppl 1): S8-S11.

Falanga A., Marchetti M. & Vignoli A. 2013. Coagulation and cancer: biological and clinical aspects. Journal of Thrombosis and Haemostasis. 11(2): 223-233.

Falanga A., Russo L. & Milesi V. 2014. The coagulopathy of cancer. Current Opinion in Hematology. 21(5): 423-429.

Falanga A., Russo L., Milesi M. & Vignoli A. 2017. Mechanisms and risk factors of thrombosis in cancer. Critical Reviews in Oncology/Hematology. (118): 79-83.

Gungor T., Kanat-Pektas M., Sucak A. & Mollamahmutoglu L. 2009. The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Archives of Gynecology and Obstetrics. 279(1): 53-56.

Kristensen A.T., Wiinberg B., Jessen L.R., Andreasen E. & Jensen A.L. 2008. Evaluation of human recombinant tissue factor activated thromboelastography in 49 dogs with neoplasia. Journal of Veterinary Internal Medicine. 22(1): 140-147.

Magnus N., D'Asti E., Meehan B., Garnier D. & Rak J. 2014. Oncogenes and the coagulation system–forces that modulate dormant and aggressive states in cancer. Thrombosis Research. 133(Suppl 2): S1-S9.

Mischke R., Wohlsein P., Busse L. & Pohlenz J. 1998. Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma. Schweizer Archivfür Tierheilkunde. 140(12): 497-505.

Neel J.A., Snyder L. & Grindem C.B. 2012. Thrombocytosis: a retrospective study of 165 dogs. Veterinary Clinical Pathology. 41(2): 216-222.

O’Donnell M.R., Slichter S.J., Weiden P.L. & Storb R. 1981. Platelet and fibrinogen kinetics in canine tumors. Cancer Research. 41(4): 1379-1383.

Rickles F.R., Levine M. & Edwards R.L. 1992. Hemostatic alterations in cancer patients. Cancer and Metastasis Reviews. 11(3-4): 237-248.

Saavedra P.V., García A.L., López S.Z. & Couto G. 2011. Hemostatic abnormalities in dogs with carcinoma: A thromboelastographic characterization of hypercoagulability. The Veterinary Journal. 190(2): e78-e83.

Stockhaus C., Kohn B., Rudolph R., Brunnberg L. & Giger U. 1999. Correlation of haemostatic abnormalities with tumor stage and characteristics in dogs with mammary carcinoma. The Journal of Small Animal Practice. 40(7): 326-331.

Stokol T., Brooks M., Erb H. & Mauldin G.E. 1999. Evaluation of kits for the detection of fibrin(ogen) degradation products in dogs. Journal of Veterinary Internal Medicine. 13(5): 478-484.

Symbas N.P., Townsend M.F., El-Galley R., Keane T.E., Graham S.D. & Petros J.A. 2000. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU International. 86(3): 203-207.

Tabak D., Torres L.G. & Nahoum B. 2011. Câncer e trombose. Onco&. 4: 26-32.

Wada H., Sase T. & Yamaguchi M. 2005. Hypercoagulant states in malignant lymphoma. Experimental Oncology. 27(3): 179-185.

Woolcock A.D., Keenan A., Cheung C., Christian J.A. & Moore G.E. 2017. Thrombocytosis in 715 Dogs (2011-2015). Journal of Veterinary Internal Medicine. 31(6): 1691-1699.




DOI: https://doi.org/10.22456/1679-9216.96674

Copyright (c) 2019 Jéssica Rodrigues de Oliveira, Annelise Carla Camplesi, Sabryna Gouveia Calazans, Aureo Evangelista Santana, Priscila Silva, Bruna Fernanda Firmo, Amanda Bizare, Márcia Ferreira da Rosa Sobreira

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.